This is a working overview of glycyl-histidyl-lysine, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
| Property | Value | Notes |
|---|---|---|
| Long-term storage | -20 °C | Dry powder, sealed and protected from light |
| Working storage | 2 to 8 °C | Short-term holding; avoid repeated warming cycles |
| Purity assay | Reversed-phase HPLC with UV detection | Detection commonly near 214 nm |
| Copper assay | ICP-OES or atomic absorption | Confirms metal content and the metal-to-peptide ratio |
| Visible absorption | Roughly 520 to 600 nm | Rapid indicator of complex integrity |
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Only 231Pa and 234Pa have been found in nature. All the isotopes have short lifetimes, except for protactinium-231 (half-life 32,760 years). The most important isotopes are 231Pa and 233Pa, which is an intermediate product in obtaining uranium-233 and is the most affordable among artificial isotopes of protactinium. 233Pa has convenient half-life and energy of γ-radiation, and thus was used in most studies of protactinium chemistry. Protactinium-233 is a β-emitter with a half-life of 26.97 days. There are 27 known isotopes of uranium, having mass numbers 215–242 (except 220). Three of them, 234U, 235U and 238U, are present in appreciable quantities in nature. Among others, the most important is 233U, which is a final product of transformation of 232Th irradiated by slow neutrons. 233U has a much higher fission efficiency by low-energy (thermal) neutrons, compared e.g. with 235U. Most uranium chemistry studies were carried out on uranium-238 owing to its long half-life of 4.4×109 years. There are 25 isotopes of neptunium with mass numbers 219–244 (except 221); they are all highly radioactive. The most popular among scientists are long-lived 237Np (t1/2 = 2.20×106 years) and short-lived 239Np, 238Np (t1/2 ~ 2 days). There are 21 known isotopes of plutonium, having mass numbers 227–247. The most stable isotope of plutonium is 244Pu with half-life of 8.13×107 years. Eighteen isotopes of americium are known with mass numbers from 229 to 247 (with the exception of 231).
1996: Insulin lispro, which was originally manufactured by Eli Lilly and Company, is granted approval. 2000: Insulin aspart, which was created by Novo Nordisk, is approved. 2000: Insulin glargine, which was developed by Sanofi-Aventis, is approved. 2004: Insulin glulisine, also developed by Sanofi-Aventis, is approved. 2005: Insulin detemir, which was formulated by Novo Nordisk, gets approval. 2015: Insulin degludec, created by Novo Nordisk, is approved. 2020: Insulin lispro-aabc, a faster insulin lispro formulation created by Eli Lilly and Company, is approved. 2021: Insulin glargine-yfgn, the first approved insulin biosimilar, which is produced by Viatris, is approved. 2021: Insulin glargine-aglr, a biosimilar produced by Eli Lilly and Company, is granted approval. 2024: Insulin icodec, the newest commercially available analogue by Novo Nordisk, gets approval. 2025: Insulin aspart-szjj, the first short-acting biosimilar, created by Viatris, is approved.
The regulation of food and dietary supplements by the U.S. Food and Drug Administration (FDA) is governed by various statutes enacted by the United States Congress. Pursuant to the Federal Food, Drug, and Cosmetic Act and accompanying legislation, the FDA has authority to oversee the quality of substances sold as food in the United States, and to monitor claims made in the labeling about both the composition and the health benefits of foods. Substances which the FDA regulates as food are subdivided into various categories, including foods, food additives, added substances (man-made substances which are not intentionally introduced into food, but nevertheless end up in it), and dietary supplements. The specific standards which the FDA exercises differ from one category to the next. Furthermore, the FDA has been granted a variety of means by which it can address violations of the standards for a given category of substances. Dietary supplement manufacture is required to comply with the good manufacturing practices established in 2007. The FDA can visit manufacturing facilities, send warning letters if not in compliance with GMPs, stop production, and if there is a health risk, require that the company conduct a recall. Only after a dietary supplement product is marketed, may the FDA's Center for Food Safety and Applied Nutrition (CFSAN) review the products for safety and effectiveness.
== Methods of detection and analysis == The most sensitive method of detecting and measuring EDTA in biological samples is selected reaction monitoring capillary electrophoresis mass spectrometry (SRM-CE/MS), which has a detection limit of 7.3 ng/mL in human plasma and a quantitation limit of 15 ng/mL. This method works with sample volumes as small as 7–8 nL. EDTA has also been measured in non-alcoholic beverages using high performance liquid chromatography (HPLC) at a level of 2.0 μg/mL.
Sources: en.wikipedia.org
In March 2016, the International Narcotics Control Board stated that the UN's international drug treaties do not mandate a "war on drugs" and that the choice is not between "'militarized' drug law enforcement on one hand and the legalization of non-medical use of drugs on the other", health and welfare should be the focus of drug policy. That April, the UN General Assembly Special Session (UNGASS) on the "World Drug Problem" was held. The Wall Street Journal assessed the attendees' positions as "somewhat" in two camps: "Some European and South American countries as well as the U.S. favored softer approaches. Eastern countries such as China and Russia and most Muslim nations like Iran, Indonesia and Pakistan remained staunchly opposed." The outcome document recommended treatment, prevention and other public health measures, and committed to "intensifying our efforts to prevent and counter" drug production and trafficking, through, "inter alia, more effective drug-related crime prevention and law enforcement measures." Under President Donald Trump (2017–2021), Attorney General Jeff Sessions reversed the previous Justice Department's cannabis policies, rescinding the Cole Memo that deferred federal enforcement in states where cannabis had been legalized He instructed federal prosecutors to "charge and pursue the most serious, readily provable offense" in drug cases, regardless of whether mandatory minimum sentences applied, which could trigger mandatory minimums for lower-level charges.
==== Pancreatic and glycemic control ==== GLP-1 receptor activation slows gastric emptying, inhibits the release of glucagon, and stimulates insulin production, thereby improving glucose homeostasis in people with type 2 diabetes. At the cellular level, binding to the GLP-1 receptor on pancreatic beta cells elevates intracellular cyclic AMP (cAMP) and activates protein kinase A (PKA). This cascade triggers the influx of calcium, which directly prompts the exocytosis of insulin-containing vesicles. Furthermore, GLP-1 agonists actively ameliorate peripheral insulin resistance by upregulating phosphorylated IRS-1 and promoting the transport of the GLUT4 transporter to cell membranes in muscle and adipose tissue.
=== Controversies === The FDA authorized use of injectable naltrexone (Vivitrol) for opioid addiction using a single study that was led by Evgeny Krupitsky at Bekhterev Research Psychoneurological Institute, St Petersburg State Pavlov Medical University, St Petersburg, Russia, a country where opioid agonists such as methadone and buprenorphine are not available. The study was a "double-blind, placebo-controlled, randomized", 24-week trial running "from July 3, 2008, through October 5, 2009" with "250 patients with opioid dependence disorder" at "13 clinical sites in Russia" on the use of injectable naltrexone (XR-NTX) for opioid dependence. The study was funded by the Boston-based biotech Alkermes firm which produces and markets naltrexone in the United States. Critics charged that the study violated ethical guidelines since it compared the formulation of naltrexone not to the best available, evidence-based treatment (methadone or buprenorphine), but to a placebo. Further, the trial did not follow patients who dropped out of the trial to evaluate subsequent risk of fatal overdose, a major health concern. Subsequent trials in Norway and the US did compare injectable naltrexone to buprenorphine and found them to be similar in outcomes for patients willing to undergo the withdrawal symptoms required before naltrexone administration. Nearly 30% of patients in the US trial did not complete induction.
== History == Delafloxacin was known as ABT-492, RX-3341, and WQ-3034 while it was under development. Rib-X Pharmaceuticals acquired delafloxacin from Wakunaga Pharmaceutical in 2006. Rib-X was renamed to Melinta Therapeutics in 2013. It was developed and marketed by Melinta Therapeutics (formerly Rib-X Pharmaceuticals), which subsequently merged with Cempra. Key clinical trials for delafloxacin have been performed by Melinta regarding indications for skin and skin structure infections as well as complicated bacterial infections and uncomplicated gonorrhea. The trial on gonorrhea was terminated before data was released. Delafloxacin was approved by the FDA in June 2017, after it was noninferior to vancomycin plus aztreonam in two trials on 1042 patients with acute bacterial skin and skin structure infection. New Drug Applications (NDA) for delafloxacin (Baxdela) 450 mg tablets and 300 mg injections were approved by the FDA in June 2017. The FDA obligated Melinta to conduct further studies as follows:
== History == The British computer scientist Alan Turing laid the theoretical groundwork for artificial intelligence. His foundational 1936 paper on the Entscheidungsproblem introduced the concept of the universal computing machine. Turing's wartime efforts at Bletchley Park involved developing the Bombe, an electromechanical device that utilized heuristic search techniques to decipher Enigma codes. In 1950, Turing published his seminal paper "Computing Machinery and Intelligence" in the journal Mind, where he proposed the "Imitation Game" (now known as the Turing Test) as a criterion for machine intelligence. This period established Britain as a global leader in early computational theory and machine intelligence. During the 1960s, the UK established AI research centers, most notably at the University of Edinburgh. In 1963, Donald Michie founded a small research group that later evolved into the Department of Machine Intelligence and Perception. Michie's team developed the Freddy robots (Freddy I and Freddy II), which were early examples of robots capable of integrating vision and manipulation to assemble objects. Researchers such as Robert Kowalski at the University of Edinburgh and later Imperial College London made significant contributions to logic programming, laying the theoretical foundations for the Prolog programming language. However, the optimism of the 1960s was curtailed by the 1973 Lighthill Report.
Sources: en.wikipedia.org
==== Epidermal receptor (Sense organ) ==== Epidermal receptors are abundant and distributed all over the epidermis. Each receptor shows a slightly elevated cuticle which covers a group of tall, slender and columnar receptor cells. These cells bear small hairlike processes at their outer ends and their inner ends are connected with nerve fibres. The epidermal receptors are tactile in function (mechanoreceptor) and can respond to touch, cuticle deformation, gravity and sound. They also respond to chemical stimuli (chemoreceptors). Earthworms are extremely sensitive to mechanical vibrations (e.g. trampling, earthquakes) which make them emerge from the soil and crawl at its surface, a reflex used by earthworm harvesters (e.g. fishers) to catch them easily.
For much of the 19th century the chainsaw was a useful surgical instrument, but it was superseded in 1894 by the Gigli twisted-wire saw, which was substantially cheaper to manufacture, and gave a quicker, narrower cut, without risk of breaking and being entrapped in the bone. A precursor of the chainsaw familiar today in the timber industry was another medical instrument developed around 1830, by German precision mechanic and orthopaedist Bernhard Heine. This instrument, the osteotome, had links of a chain carrying small cutting teeth with the edges set at an angle; the chain was moved around a guiding blade by turning the handle of a sprocket wheel. As the name implies, this was used to cut bone.
The new tools of molecular biology changed the study of bird systematics, which changed from being based on phenotype to the underlying genotype. The use of techniques such as DNA–DNA hybridization to study evolutionary relationships was pioneered by Charles Sibley and Jon Edward Ahlquist, resulting in what is called the Sibley–Ahlquist taxonomy. These early techniques have been replaced by newer ones based on mitochondrial DNA sequences and molecular phylogenetics approaches that make use of computational procedures for sequence alignment, construction of phylogenetic trees, and calibration of molecular clocks to infer evolutionary relationships. Molecular techniques are also widely used in studies of avian population biology and ecology.
== Signs and symptoms == Hypoglycemic symptoms are divided into two main categories. The first category is symptoms caused by low glucose in the brain, called neuroglycopenic symptoms. The second category of symptoms is caused by the body's reaction to low glucose in the blood, called adrenergic symptoms.
Sources: en.wikipedia.org
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.
The colour comes from electronic transitions between the copper ion and the surrounding peptide nitrogen atoms. The resulting absorption sits in the visible region, giving the solid and its solutions a blue to violet appearance. Loss of colour can indicate that the copper has dissociated from the peptide.
Chromatography establishes the identity and purity of the peptide, while elemental analysis establishes the copper content. The two results should agree with a one-to-one ratio. Visible spectroscopy adds a quick check that the complex itself is intact.
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the most common approach. Purity is expressed as a share of total peak area at a specified wavelength. Mass spectrometry is then used to confirm molecular identity.